category,datetime,headline,id,image,related,source,summary,url
company,1769306917,A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Analyst Upgrades And CASGEVY Approval,138250057,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,VRTX,Yahoo,"Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise and newer assets, including the approval of CASGEVY and orphan drug status for the kidney therapy povetacicept. See our latest analysis for Vertex Pharmaceuticals. Those upgrades and regulatory milestones have landed against a backdrop of steady share price gains, with the stock at US$468.41 and a 90 day share price return of 11.48%. The 5 year total shareholder return...",https://finnhub.io/api/news?id=23d71230b55573010ca4eac88052abbf8ce4a94aa71a7d6f6a91c05cc984f9bf
